ReviewFrontiers in immunology2025
Fundamental and emerging insights into innate and adaptive immunity in inflammatory bowel diseases.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A GABARAP-PtdIns3K-C1 positive feedback loop at the heart of the phagophore nucleation.Nature communications · 2026Article
- Review
- Hydrodynamic Delivery of IL-10 Gene for Local Immunomodulation in Human Crohn's Disease Tissue: A Proof-of-Concept Study.Pharmaceutics · 2026Article
- miR-369-3p Modulates LRRK2-Mediated Inflammation and Autophagy in RAW264.7 Macrophages.International journal of molecular sciences · 2026Article
- Inflammatory, Nutritional, and Atherogenic Profiles Associated with Histologic Activity in Inflammatory Bowel Disease.Biomedicines · 2026Article
- Intestinal epithelial Smad7 drives purine metabolic dysregulation and ileal inflammation.Journal of biomedical science · 2026Article
- Understanding Frailty in IBD: Implications for Clinical Outcomes and Multidisciplinary Care.Journal of clinical medicine · 2026Review
- A pro-inflammatory neutrophil subpopulation drives intestinal ischemia-reperfusion injury via the ATF4-mediated endoplasmic reticulum stress pathway.Scientific reports · 2026Article
- Longitudinal Evidence of Sustained Taurine Deficiency in Inflammatory Bowel Disease.International journal of molecular sciences · 2026Article
- iNOS/Arg-1 balance and sIgA levels are associated with intestinal mucosal immune defense in children chronically exposed to air pollutants and lead.Frontiers in immunology · 2026Article
- Targeted expression of the immunomodulatory peptide Scy by engineeredFrontiers in immunology · 2026Article
- Cross-Disciplinary Mechanistic Insights in Molecular Medicine.Current issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBD) are chronic and disabling disorders of the gastrointestinal tract of unknown aetiology, in which the pathologic process is triggered by multiple environmental and genetic factors that activate an excessive innate and adaptive immune response against luminal antigens. In recent years, great progress has been made in the identification of factors/mechanisms underlying the amplification of the key immune steps in IBD tissue, and this has facilitated the development of several immune-related biotherapeutic compounds that have largely improved the management of the more severe forms of IBD. However, nearly half of these patients are refractory or intolerant to novel immunotherapeutics, indicating the need for further characterization of the IBD-associated detrimental immune response to develop new therapeutics. In this article, we review the available evidence about the contribution of innate and adaptive immune cells in the development of intestinal tissue damage. We also discuss the more recent findings in the field of IBD-associated immunity, which might help identify novel pathways to be manipulated for therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.